# Better Evidence for Selecting Transplant Fluids

> **NCT03829488** · PHASE3 · COMPLETED · sponsor: **The University of Queensland** · enrollment: 808 (actual)

## Conditions studied

- End Stage Kidney Disease
- Delayed Graft Function
- Kidney Transplant; Complications

## Interventions

- **DRUG:** Plasma-Lyte 148 (approx. pH 7.4) IV Infusion
- **DRUG:** 0.9% SODIUM CHLORIDE 9g/L injection BP

## Key facts

- **NCT ID:** NCT03829488
- **Lead sponsor:** The University of Queensland
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-26
- **Primary completion:** 2021-07-29
- **Final completion:** 2022-05-03
- **Target enrollment:** 808 (ACTUAL)
- **Last updated:** 2024-10-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03829488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03829488, "Better Evidence for Selecting Transplant Fluids". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03829488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*